

Development of new *P. aeruginosa* interventions

Join us in this workshop, aimed at product developers working on new interventions against *P. aeruginosa* in the early preclinical development phase. The goal is to connect participants and speakers, establish potential collaborations, and provide expert insights.

To make the most of everyone's time and presence, the event will take place in Basel just before the 10th AMR Conference — a perfect opportunity to meet while many of us are already gathered.

Monday, March 2nd 2026

10am - 04.30pm

Where?

D-BSSE (ETH Zürich)
Klingelbergstrasse 48,
4056 Basel

Organized by:



Kindly sponsored by:



Programme

Pre-Conference Workshop 2026

Development of new *P. aeruginosa* interventions

10.00am - 12.00pm		Arrival, Coffee & Lunch
12.00 - 12.05pm		Welcoming remarks
12.05 - 12.15pm		Workshop background and goals
12.15 - 12.45pm		Lecture 1: “Impact of Pseudomonas in cystic fibrosis and therapeutic strategy” Kevan O'Connor & David Nichols, Cystic Fibrosis Foundation, USA
12.45 - 1.15pm		Lecture 2: “Clinical development of Pseudomonas selective antibiotics” Glenn Dale, Bioversys, CH
1.15 - 1.45pm		Lecture 3: “Engineering Advances in Transwell Based Models for Physiologically Relevant Infection Studies” Amanzhol Kurmashev, D-BSSE, CH
1.45 - 2.30pm		Coffee break and interaction with the speakers
2.30 - 3.00pm		Lecture 4: “Indication scoping & asset valuation” Diana Stukalkina, BioScience Valuation, DE
3.00 - 3.30pm		Lecture 5: “Early regulatory engagement to plan for clinical trials” Stefan Blesse, Granzer regulatory consulting & services, DE
3.30 - 4.30pm		Interaction with the speakers

Your participation is key to the success of this event! Please confirm your attendance until February 20th 2026.

We are looking forward to seeing you there.



 comms@incate.net

 www.incate.net

 @INCATE

 @INCATE